Co Diagnostics (Germany) Performance
| C97 Stock | EUR 5.16 0.00 0.00% |
Co Diagnostics holds a performance score of 4 on a scale of zero to a hundred. The firm owns a Beta (Systematic Risk) of -0.7, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Co Diagnostics are expected to decrease at a much lower rate. During the bear market, Co Diagnostics is likely to outperform the market. Use Co Diagnostics market risk adjusted performance, semi deviation, variance, as well as the relationship between the mean deviation and downside deviation , to analyze future returns on Co Diagnostics.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Co Diagnostics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Co Diagnostics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Quick Ratio | 18.00 | |
| Fifty Two Week Low | 5.78 | |
| Fifty Two Week High | 17.00 |
C97 |
Co Diagnostics Relative Risk vs. Return Landscape
If you would invest 900.00 in Co Diagnostics on October 15, 2025 and sell it today you would lose (384.00) from holding Co Diagnostics or give up 42.67% of portfolio value over 90 days. Co Diagnostics is currently producing 2.1989% returns and takes up 38.4684% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than C97, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Co Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Co Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Co Diagnostics, and traders can use it to determine the average amount a Co Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0572
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | C97 | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 38.47 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.2 actual daily | 44 56% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Co Diagnostics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Co Diagnostics by adding it to a well-diversified portfolio.
Co Diagnostics Fundamentals Growth
C97 Stock prices reflect investors' perceptions of the future prospects and financial health of Co Diagnostics, and Co Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on C97 Stock performance.
| Return On Equity | 76.64 | |||
| Return On Asset | 48.56 | |||
| Profit Margin | 47.97 % | |||
| Operating Margin | 52.10 % | |||
| Current Valuation | 202.65 M | |||
| Shares Outstanding | 28.67 M | |||
| Price To Earning | 5.79 X | |||
| Price To Book | 3.13 X | |||
| Price To Sales | 2.17 X | |||
| Revenue | 96.35 M | |||
| EBITDA | 50.42 M | |||
| Cash And Equivalents | 72.38 M | |||
| Cash Per Share | 2.51 X | |||
| Book Value Per Share | 2.34 X | |||
| Cash Flow From Operations | 53.21 M | |||
| Earnings Per Share | 1.26 X | |||
About Co Diagnostics Performance
By analyzing Co Diagnostics' fundamental ratios, stakeholders can gain valuable insights into Co Diagnostics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Co Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Co Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. CO DIAGNOSTICS operates under Diagnostics Research classification in Germany and is traded on Frankfurt Stock Exchange. It employs people.Things to note about Co Diagnostics performance evaluation
Checking the ongoing alerts about Co Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Co Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Co Diagnostics is way too risky over 90 days horizon | |
| Co Diagnostics appears to be risky and price may revert if volatility continues |
- Analyzing Co Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Co Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Co Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Co Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Co Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Co Diagnostics' stock. These opinions can provide insight into Co Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for C97 Stock analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |